Safety, efficacy and pharmacokinetics of repeat subcutaneous dosing of avexitide (exendin 9-39) for treatment of post-bariatric hypoglycaemia.
Marilyn TanCynthia LamendolaRoger LuongTracey L McLaughlinColleen M CraigPublished in: Diabetes, obesity & metabolism (2020)
In patients with PBH, twice-daily administration of SC avexitide effectively raised the glucose nadir and prevented severe hypoglycaemia requiring rescue intervention. Avexitide may represent a viable therapy for PBH.